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Agonist antibodies activating the Met receptor protect
cardiomyoblasts from cobalt chloride-induced
apoptosis and autophagy
S Gallo1,4, S Gatti1,4, V Sala1, R Albano2, P Costelli3, E Casanova2, PM Comoglio*,1,2 and T Crepaldi*,1
Met, the tyrosine kinase receptor for hepatocyte growth factor (HGF), mainly activates prosurvival pathways, including
protection from apoptosis. In this work, we investigated the cardioprotective mechanisms of Met activation by agonist
monoclonal antibodies (mAbs). Cobalt chloride (CoCl2), a chemical mimetic of hypoxia, was used to induce cardiac damage in
H9c2 cardiomyoblasts, which resulted in reduction of cell viability by (i) caspase-dependent apoptosis and (ii) – surprisingly –
autophagy. Blocking either apoptosis with the caspase inhibitor benzyloxycarbonyl-VAD-fluoromethylketone or autophagosome
formation with 3-methyladenine prevented loss of cell viability, which suggests that both processes contribute to
cardiomyoblast injury. Concomitant treatment with Met-activating antibodies or HGF prevented apoptosis and autophagy.
Pro-autophagic Redd1, Bnip3 and phospho-AMPK proteins, which are known to promote autophagy through inactivation of the
mTOR pathway, were induced by CoCl2. Mechanistically, Met agonist antibodies or HGF prevented the inhibition of mTOR and
reduced the flux of autophagosome formation. Accordingly, their anti-autophagic function was completely blunted by
Temsirolimus, a specific mTOR inhibitor. Targeted Met activation was successful also in the setting of low oxygen conditions,
in which Met agonist antibodies or HGF demonstrated anti-apoptotic and anti-autophagic effects. Activation of the Met pathway
is thus a promising novel therapeutic tool for ischaemic injury.
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Hypoxia is critical in many pathological conditions including
myocardial ischaemia.1 Cells respond to hypoxia by activation
of the hypoxia-inducible factor HIF-1a, a transcription factor
that modulates the expression of genes involved in angio-
genesis, survival, metabolism and cell migration.2–4 In the
normoxic state the HIF-1a protein is hydroxylated, ubiquiti-
nated and degraded in the proteasome.1 In the hypoxic state
the activity of specific hydroxylases is quenched and HIF-1a is
stabilized.5 It is known that cobalt, a transition metal, mimics
hypoxia by causing inactivation of hydroxylase enzymes and
stabilization of HIF-1a.6
Although the acute hypoxic response enhances cell survival
and promotes adaptation to low oxygen environment, chronic
or extreme hypoxic conditions initiate cell death program(s),
among which apoptosis is the best known.7 Apoptosis is
governed by a series of specialized proteins, functionally
divided into pro-apoptotic (Bax) and anti-apoptotic (Bcl-2)
molecules.8 Autophagy – that is, degradation of damaged
proteins and intracellular organelles – is a less renowned
regulator of cell viability.9 In the initial phase of stress
conditions, autophagy exerts a protective function for cell
survival.10 Chronic activation of autophagy – on the contrary –
results in enhanced cell death, through mechanism(s) that are
not fully understood.11
Cardiomyocytes are sensitive to survival factors such as
hepatocyte growth factor (HGF).12 The biological functions of
HGF are mediated by a specific tyrosine kinase receptor,
encoded by the MET proto-oncogene and by activation of
multiple intracellular downstream signalling pathways.13 The
HGF/Met axis is normally silent in terminally differentiated
cardiomyocytes; however, it is induced and activated when the
organ undergoes injury, including ischaemia.12,14 Moreover, it
is known that Met is an inducible gene and that the promoter is
activated by five Hypoxia Response Elements sensitive to
HIF-1a.4 It has been proposed that HGF may be cardioprotective,
attenuating ischaemia/reperfusion injury.15 Agonist mono-
clonal antibodies (mAbs) directed against the cell surface Met
receptor stimulate receptor homodimerization, autophosphor-
ylation and consequently kinase activation through their
divalent nature.16,17 In the present study, we show that such
antibodies vicariate HGF in protecting cardiac muscle cells
from hypoxic injury. Unexpectedly, their prosurvival role is
1Department of Oncology, University of Turin, Turin, Italy; 2Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy and 3Department of Clinical and Biological Sciences,
University of Turin, Turin, Italy
*Corresponding author: PM Comoglio, Candiolo Cancer Institute, FPO-IRCCS, Street Provinciale 142, km 3.95, Candiolo 10060, Italy. Tel:þ 39 011 993 3601;
Fax:þ 39 011 962 1525; E-mail: pcomoglio@gmail.com or T Crepaldi, Institute of Anatomy, Corso Massimo d’Azeglio 52, Turin 10126, Italy. Tel:þ 39 011 670 7773;
Fax:þ 39 011 236 7773; E-mail: tiziana.crepaldi@unito.it
4These authors contributed equally to this work.
Received 19.8.13; revised 05.3.14; accepted 06.3.14; Edited by GM Fimia
Keywords: HGF receptor; hypoxia; apoptosis; autophagy; mTOR
Abbreviations: Baf, Bafylomicin A1; CoCl2, cobalt chloride; HGF, hepatocyte growth factor; LC3, microtubule-associated protein light chain 3; mAbs, monoclonal
antibodies; MTT assay, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay; PHA, PHA-665752; Tem, Temsirolimus; zVAD (zVAD fmk),
benzyloxycarbonyl-VAD-fluoromethylketone; 3-MA, 3-methyladenine
Citation: Cell Death and Disease (2014) 5, e1185; doi:10.1038/cddis.2014.155
& 2014 Macmillan Publishers Limited All rights reserved 2041-4889/14
www.nature.com/cddis
mediated not only by the known anti-apoptotic activity but by
protection from autophagic damage as well.
Results
Met agonist antibodies stimulate receptor phosphorylation,
downstream signalling and biological response in
cardiomyoblasts. To assess the role of Met in cardiac
protection from hypoxia injury, we studied the H9c2 rat
cardiomyoblasts. These cells express cardiac markers Con-
nexin43 and Troponin-I (Supplementary Figure S1a). First, we
demonstrated using flow cytometry that the endogenous Met
receptor is present at the cell surface (Figure 1a). Moreover,
immunofluorescence (IF) analysis showed that Met is
localized both at the plasma membrane and intracellularly
(Supplementary Figure S1b). Second, we stimulated the Met
tyrosine kinase activity by using the HGF ligand or two mAbs,
DN30 and DO24, which we previously showed to be partial
and full agonist of the Met receptor, respectively.16 All three
Met agonists induced phosphorylation of Met (Figure 1b),
activation of its principal effector Gab1 (Figure 1b) and
stimulation of the main signalling pathways downstream Met
(that is, Akt, Erk and mTOR, data not shown). In a classical
‘wound-healing’ assay, treatment with either mAb induced
cells to migrate and to cover the wounded area at an extent
similar to that induced by HGF (Figure 1c). As a control,
treatment with an irrelevant (anti-VSV-G) antibody had no
effect on cell migration (Supplementary Figure S2a).
CoCl2 induces cardiomyoblast apoptosis. CoCl2 mimics
the hypoxic/ischaemic condition and is a simple and
validated in vitro tool to study the molecular mechanisms
driven by hypoxia.18 Indeed, after CoCl2 treatment, HIF-1a
protein expression significantly increased, starting from 3 h
(Supplementary Figure S3a), whereas mRNA level was
super-induced at later time (starting from 12 h;
Supplementary Figure S3b). To further assess the involve-
ment of HIF-1a in CoCl2 response, we analysed the
expression of known typical HIF-1a target genes, such as
Glut1, CAXII, GAPDH and Met itself.4,19–21 In time course
experiments, a significant increase in mRNA levels was
observed at 3 h for Glut1 and at 12 h for CAXII and Met
(Supplementary Figure S3c–e). Induction of GAPDH protein
was detected at 24 h (Supplementary Figure S3f). To
investigate the CoCl2 effect on cell viability, we performed
the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) assay. Cardiomyoblasts treated with CoCl2
showed a significant reduction in cell survival in a dose- and
time-dependent manner (Figures 2a and b). Moreover, CoCl2
decreased prosurvival pathways (that is, Akt, Erk and
mTOR), which are stimulated by HGF-activated Met receptor
(Supplementary Figure S4). Consistently, CoCl2 treatment
significantly impaired the signalling response to HGF survival
factor (Supplementary Figure S4). As it is known that hypoxia
produces cell death through mitochondrial membrane per-
meabilization,22 we analysed the apoptotic response. We
found that treatment with CoCl2 leads to a significant
increase in the number of pyknotic nuclei, as compared with
untreated cells (Figure 2c); this apoptotic event was
mediated by the caspase-dependent pathway of cell death,
as it was affected by the specific inhibitor zVAD (Figure 2d).
We also analysed the ratio between Bax and Bcl-2 protein
levels, known to be crucial in caspase-mediated apoptosis.
The treatment with CoCl2 increased the pro-apoptotic Bax
and decreased the anti-apoptotic Bcl-2 at early (12 h) and
late (48 h) time points, resulting in a significant enhancement
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Figure 1 H9c2 cells express the Met receptor and are responsive to the treatment with Met agonists. (a) Flow cytometry detection of Met expression on cell surface. The
99.85% of viable cells showed a high immunofluorescence signal for the anti-HGF receptor antibodies. (b) Phosphorylation of Met and Gab1 is induced by HGF, DN30 and
DO24. The cells were treated briefly (300 0 and 600 0) with 0.5 nM HGF, 100 nM DN30 and DO24. Met and Gab1 IPs were analysed by WB with p-Met, Met and p-Tyr, Gab1
antibodies, respectively. Tubulin was used as loading control for the input lysates. (c) Wound-healing assay in cells treated or not (NT, white) for different lengths of time with
DN30 (100 nM, light grey), DO24 (100 nM, middle grey) or HGF (0.5 nM, dark grey). Values are the mean±S.D. of three independent experiments. t-test was calculated
between treated samples versus NT control at each time point. **Po0.01 and ***Po0.005
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of Bax/Bcl-2 ratio (Figure 2e). Consistent with the activation
of the canonical mitochondrial pathway of apoptosis, the ratio
between the cleaved and the total caspase-3 protein was
significantly raised in cells treated for 48 h (Figure 2f). Finally,
the ratio between cleaved and uncleaved PARP, one of the
substrates of caspase-3, significantly increased at 72 and
96 h (Figure 2g).
Met agonist antibodies protect from CoCl2-induced
apoptosis. To restore the prosurvival signalling and protect
cardiomyoblasts from apoptosis, we concomitantly treated
cells with CoCl2 and Met agonist antibodies or HGF. Met
stimulation by either mAb or HGF fully prevented the loss of
cell viability in the MTT assay (Figure 3a). The PHA-665752
(PHA), a specific inhibitor of the Met kinase, abolished the
prosurvival activity of Met agonist antibodies and HGF; thus,
protection was mediated specifically by the Met receptor
(Figure 3a). We also demonstrated that the two mAbs, as well
as HGF, protected from CoCl2-induced reduction of cell
number (Figure 3b). As a control the treatment with anti-
VSV-G antibody did not produce any effect (Supplementary
Figure S2b and c). Importantly, DN30, DO24 and HGF
prevented the CoCl2-induced rise in the number of pyknotic
nuclei (Figure 3c). Accordingly, all above Met agonists
prevented caspase-3 activation induced by CoCl2 (Figure 3d).
CoCl2 induces autophagy contributing to cardiomyoblast
death. In our experiments, the apoptosis inhibitor zVAD
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Figure 2 CoCl2 induces apoptosis in H9c2 cardiomyoblasts. Cell viability was evaluated through MTT analysis of (a) CoCl2 dose-dependent treatment for 24 h and
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failed to fully inhibit cell death (Figure 2d). This observation
suggested that the caspase-dependent apoptosis only par-
tially contributes to the loss of cell viability induced by CoCl2. It
has been reported that prolonged stimulation of the HIF-1a
pathway produces excess autophagy, which may also result in
cell death.23 Thus, we evaluated the induction of pro-
autophagic mechanisms in cells treated for different lengths
of time with CoCl2. We performed an mRNA expression
analysis of Redd1 and Bnip3, known transcriptional targets of
HIF-1a,24,25 which promote autophagy by inhibition of
mTOR.26,27 Both genes were significantly induced by CoCl2
treatment starting from 12 h and were maintained at high
levels for 48 h (Figures 4a and b). Redd1 and Bnip3 protein
levels were also increased in presence of CoCl2 (Figures 4c
and d). Another HIF-1a-dependent mechanism of autophagy
induction is mediated by AMPK phosphorylation and activa-
tion.28 We found that CoCl2 treatment induced a significant
increase in AMPK phosphorylation, relative to untreated cells
(Figure 4e). It is known that P-AMPK is also an inhibitory
molecule of the mTOR pathway;29 thus, we analysed the
phosporylation state of p70S6K and 4EBP1, the two main
substrates of mTOR. Phosphorylation levels of both proteins
were significantly decreased in a time-dependent manner by
CoCl2 treatment, starting from 24 h (Figures 4f and g). This
result indicates that CoCl2 treatment induces the inhibition of
the mTOR pathway. As negative regulation of mTOR
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signalling promotes autophagy30 we analysed some key
proteins of different phases of autophagosome formation.
Autophagy is positively regulated by Beclin-1, which binds the
class III PI3K Vps34, thereby facilitating autophagosome
formation.31 Another phase of autophagy is the elongation of
the autophagosome, with generation of the lipidated form of
LC3 called LC3II.32 Finally, p62/SQSTM1 protein is an
important marker of the autophagic machinery, as it recog-
nizes ubiquitin and determines the cargo of ubiquitinated
substrates in the autophagic–lysosomal pathway.33 Accord-
ingly, we observed that both Beclin-1 and p62 protein levels
were induced in CoCl2-treated cells (Figures 5a and c) and
that LC3 was processed from the inactive (LC3I) to the active
form (LC3II, Figure 5b) in a time-dependent manner. In
addition, the mRNAs of these autophagic proteins were
induced in the presence of CoCl2 for 48 h (Figure 5d).
Moreover, IF analysis revealed that CoCl2 induced LC3
puncta formation, proof of autophagosome maturation
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(Supplementary Figure S5A and B). Finally, we asked
whether increased autophagic response could participate into
the CoCl2-induced loss of cell viability. We co-treated
cardiomyoblasts with CoCl2 and 3-Methyladenine (3-MA),
a selective inhibitor of the autophagic initiator PI3K
type III. The inhibitor decreased the LC3 puncta formation
(Supplementary Figure S5B and C) and, importantly, pre-
vented the loss of cell viability and recovered as much as 80%
of the basal value (Figure 5e). This last result indicates that,
besides apoptosis, the autophagic process is involved in cell
death induced by CoCl2. The increase in pro-autophagic
proteins by hypoxic injury may be due to either enhanced
formation or reduced degradation of autophagosomes. Treat-
ment with bafilomycin A1 (Baf), an inhibitor of the vacuolar Hþ
ATPase of lysosomes,34 significantly increased the LC3II/LC3I
ratio (Figure 5f), indicating a block on the basal lysosomal-
dependent degradation of the autophagosome cargo. H9c2
cells concomitantly treated with CoCl2 and Baf showed
LC3II/LC3I protein levels and LC3 immunofluorescent puncta
significantly higher than those observed in cells treated with
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CoCl2 alone (Figure 5f and Supplementary Figure S5B and D).
Altogether, these data suggest that CoCl2-induced death
results from enhanced flux of autophagosome formation
rather than from reduced clearance.
Met agonist antibodies protect from CoCl2-induced
autophagy through the mTOR pathway. Treatment with
DN30, DO24 or HGF prevented the increase of both LC3II/
LC3I ratio and p62 protein levels (Figures 6a and b). These
results demonstrate that Met agonists inhibit the autophagy
induced by CoCl2. To investigate the effect of HGF stimula-
tion on the autophagic flux we again used the Baf inhibitor. In
cell cultures exposed to Baf or BafþCoCl2, the addition of
HGF resulted in a significantly lower LC3II/LC3I ratio as
compared with the corresponding treatment in the absence of
the cytokine (Figure 6c). Lysosomal proteolysis was com-
pletely blocked by Baf; thus, an LC3II decrease below the
Baf-induced levels indicates that HGF reduces the flux of
autophagosome formation. The two Met agonist antibodies
also decreased the LC3II/LC3I ratio in cells cultured in
the presence of CoCl2 and Baf (Figure 6d). To identify the
protective signalling involved in Met agonist action, we
blocked the mTOR pathway known to be the main inhibitor
of autophagy. In the presence of temsirolimus, a specific
inhibitor of the mTOR complex, the Met agonist-mediated
recovery of cell viability upon hypoxic injury was abrogated
(Figure 7a). The level of mTOR activation in cultures
exposed to CoCl2 in combination with Met agonists was
higher than in cells treated with CoCl2 alone (Figures 7b and c).
In contrast, the Met agonist antibodies- or HGF-mediated
mTOR activation was completely blunted by temsirolimus
(Figures 7b and c). Accordingly, the Met agonist-mediated
recovery of LC3II/LC3I ratio from CoCl2-induced autophagy
was reduced by mTOR pathway inhibition (Figure 7d).
Altogether, these results indicate that mTOR activation has
a key role in the Met-stimulated protection from autophagy.
Met agonist antibodies attenuate apoptosis and
autophagy under hypoxic conditions. The cardioprotective
action of the two Met agonist antibodies as well as HGF
was evaluated under hypoxic environment at 1% of oxygen
tension (Figure 8). First, we showed that hypoxic treatment
produced reduction of cell viability (Figure 8a), increase of
pycnotic nuclei (Figure 8b) and induction of pro-autophagic
proteins Redd1 and Bnip3 (Figure 8c). Next, we demon-
strated that Met stimulation by the two mAbs as well
as HGF under hypoxic conditions ameliorates cell viability
(Figure 8d), reduces the number of pyknotic nuclei (Figure 8e)
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and decreases the level of autophagic ratio LC3II/LC3I and
p62 (Figure 8f). In conclusion, these results show that Met
agonists have anti-apoptotic and anti-autophagic effects also
in low oxygen tension conditions.
Discussion
The effect of hypoxia in cardiomyocytes relies on duration and
intensity of hypoxic stimulus. Short-term induction of HIF-1a is
beneficial, as the injured myocardium metabolically adapts to
hypoxic condition.35 In contrast, long-term stabilization of
HIF-1a may be detrimental.35–38 Accordingly, we found that
sustained hypoxic injury is followed by cardiomyoblast grief.
It is known that HIF-1a stabilization sensitizes tumour and
neuronal cells to programmed cell death.39,22 The mechanisms
at the basis of HIF-1a apoptotic effect are not yet well
understood but presumably involve Bnip3,40 p5341 and
increased production of ROS.42 All these processes converge
on the activation of the intrinsic pathway of apoptosis. We found
that treatment with CoCl2 induced a significant rise of pyknotic
nuclei with concomitant increase in the Bax/Bcl-2 ratio followed
by activation of caspase-3 cleavage. Blocking caspases
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through a chemical inhibitor significantly improved cell viability,
validating the apoptotic pathway as a relevant factor in the
CoCl2 hypoxic mimicking model.
Here we show that CoCl2-induced hypoxia – besides
apoptosis – is also a strong inducer of autophagy. In fact,
chemical hypoxia increases known markers of the
autophagic–lysosomal pathway: Beclin-1 (an indicator of
autophagy induction), conversion of LC3I to lipidated LC3II
(an index of autophagosome abundance) and p62 (a marker
of ubiquitinated substrate sequestration and degradation).31–33
Moreover, cell death induced by CoCl2 was blocked by
3-MA, an inhibitor of the class III PI3K Vps34, a canonical
initiator of autophagy. The latter experiment indicates
that autophagy causes uncontrolled ‘self-cannibalism’ in
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cardiomyoblasts and contributes to cell death. We also
enlightened the cross-talk between apoptotic and autophagic
pathways, as CoCl2 decreases Bcl-2 and concomitantly
induces Bnip3 and Beclin-1, known triggers of autophagy. In
fact, it is reported in the literature that Beclin-1 is inhibited by
Bcl-243 and, in turn, Bcl-2 is associated with and inhibited by
Bnip3.44
The main regulator of autophagy is mTOR, a potent sensor
and integrator of signals stimulated by growth factors,
nutrients and energy status. Under conditions of nutrient
availability and normoxia, mTOR is active and phosphorylates
ATG13, preventing its association with ULK and formation of
the autophagosome.45 We found that both CoCl2 and real
hypoxia promote upregulation of Bnip3 and Redd1, two
different hypoxia-inducible target genes. It is known from the
literature that these two proteins inhibit Rheb, a Ras-related
small GTPase, and, as a consequence, lead to a negative
regulation of mTOR. Bnip3 directly binds and inhibits Rheb,27
while Redd1 acts through a not-yet-defined mechanism
involving TSC1/2, an inhibitor of Rheb.26 We also demon-
strated that CoCl2 induces phosphorylation and activation of
AMPK, another negative regulator of mTOR.29
HGF has been proposed as a cardioprotective factor.12,46–50
Patient administration of biologically active HGF may however
be difficult as it is a large molecule containing a heparin-
binding domain sequestered by low affinity–high avidity sites
widespread among the extracellular matrix proteo-
glycans.51,52 Moreover, HGF is produced as an inactive
precursor that has to be activated after cleavage by specific
convertases.53 Compared with the natural HGF ligand, the
mAbs have a major advantage of being easier to be produced
and more manageable for the therapeutic formulation. For
agonist antibodies, their divalent nature is a benefit as they
dimerize and activate the receptors. This property has been
scrutinized in detail in the case of anti-Met antibodies in the
effort of generating monovalent fully inhibitory Fabs, success-
fully employed in preclinical cancer therapy.17
Here we show that either HGF or the Met agonist antibodies
DN30 and DO24 protect from caspase-dependent apoptosis
as well as autophagy. The protection from autophagy is
mediated by activation of mTOR. Consistently, the increase
in phospho-p70S6K and phospho-4EBP1 levels and
the inhibition of autophagic LC3 lipidation were abrogated by
the mTOR inhibitor. It is likely that activation of mTOR is
triggered by the PI3K/Akt pathway at different levels, such as
the regulation of mTOR/Raptor complex or phosphorylation of
TSC2.54,55 In addition, Erk inhibits the TSC1/2 complex.56
Met agonist antibodies represent a new important tool
enriching the therapeutic arsenal to manage cardiac
diseases. Apoptosis is harmful in the reperfusion phase of
myocardial infarction.57 Furthermore, apoptosis is involved
also in a wide spectrum of inherited cardiomyopathies,
myocarditis, transplant rejection and heart failure.58 Met
agonist antibodies prove to be effective in inhibiting autophagy
as well, a less considered mechanism of cell damage in heart
diseases. While several studies have reported that basal
levels of autophagy are required for cardiac homoeostasis,59
induction of autophagic flux in response to ischaemia/
reperfusion insult is detrimental;11,60 thus, new tools against
autophagic damage are desirable. This work provides a novel
therapeutic approach to cardiac diseases that offers
molecules displaying a dual mechanism of prosurvival activity.
Materials and Methods
Reagents. The rat cardiomyoblasts cell line H9c2 was purchased from the
American Type Culture Collection (ATCC, Manassas, VA, USA). The two Met
agonist mAbs (DN30 and DO24) were produced by one of us (RA) from
hybridomas obtained with the fusion between the immune spleen cells from Balb/c
mice (Charles River Laboratories, Wilmington, MA, USA) immunized with GTL-16
cells, where the MET proto-oncogene is amplified and overexpressed, and the
P3.X63.Ag8.653 myeloma cells. The purification and selection of the antibodies
were performed as described in Prat et al.16 HGF was acquired from Tebu-Bio
(Le-Perray-en-Yvelines, FR), whereas CoCl2 and anti-VSV-G mAb were from
Sigma (St. Louis, MO, USA). CoCl2 was dissolved in water. Met tyrosine kinase
inhibitor PHA-665752 (PHA, 500 nM) was supplied by Pfizer (New York, NY,
USA). mTor inhibitor Temsirolimus was used at 1 mM and purchased from Sigma.
The following inhibitors were purchased from Sigma: zVAD (caspase inhibitor,
50mM), 3-MA (inhibitor of class III PI3K Vps34, 1 mM) and Baf (inhibitor of the
lysosomal vacuolar Hþ ATPase, 50 nM).
Cell culture and treatment. H9c2 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM, Sigma) supplemented with 10% fetal bovine serum (FBS,
Sigma), 1% penicillin (Sigma), 1% streptomycin (Sigma) and 1% L-Glutamine
(Sigma) and were incubated under 5% CO2 at 37 1C. Cells were passed regularly
and subcultured to B80/90% of confluence before all the experiments.
To mimic hypoxic conditions, the cell culture was starved with 0.5% FBS and then
treated with CoCl2 at various concentrations and for different lengths of time. In real
hypoxia experiments, cells were cultured at low oxygen tension (1%) in a HeraCell
(AHSI, Bernareggio, MB, Italy) incubator. HGF (0.5 nM) and the two Met agonist
antibodies (DN30 and DO24, 100 nM) were administrated alone or concomitantly
with the hypoxic treatment. The mAb against the VSV-G (100 or 300 nM) was used
as control.
Immunoprecipitation (IP) and immunoblot (WB) analyses. Cells
were lysed in two types of ice-cold lysis buffers: the not denaturant Dim Buffer for
IP analysis and the RIPA Buffer for direct WB experiments, both added with
protease inhibitor cocktail (Sigma). Cell lysates were subsequently sonicated and
centrifuged at 14 000 r.p.m. (20 min at þ 4 1C). The protein concentration was
evaluated through the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA,
USA). For the IP analysis, 1.2 mg of cell lysates were incubated overnight at
þ 4 1C with 5 mg DN30 and DO24 for Met IP or with 5 mg anti-Gab1 antibody
(Millipore, Billerica, MA, USA) for Gab1 IP. Then, 20 ml of protein G sepharose
(GE-healthcare, Little Chalfont, BKM, UK) were added and incubated for 2 h at
þ 4 1C. The WB and IP lysates were separated using SDS-PAGE and transferred
to Hybond-P pvdf membrane (Amersham plc, Amersham, BKM, UK). After
incubation in blocking solution (10% bovine serum albumin, BSA, Sigma) at room
temperature (RT), membranes were incubated overnight at þ 4 1C with the
primary antibodies (see Supplementary Table S1). Membranes were washed and
then incubated with specific horseradish peroxidase-conjugated secondary
antibodies (Amersham) for 1 h at RT. The proteins were revealed by enhanced
chemiluminescence of the ECL Prime detection kit (GE-healthcare) and quantified
with the Image Lab software (Bio-Rad Laboratories).
Analysis of cell death: MTT assay, DAPI stain and cell count.
Cell viability was evaluated using the MTT quantitative colorimetric assay (Roche
Applied Science, Indianapolis, IN, USA). The absorbance of the converted purple
formazan crystals from the yellow solution was measured at 595 nm.
Pyknosis was evaluated through DAPI stain. Cells, after washing with phosphate-
buffered saline (PBS), were fixed with 95% ethanol for 10 min at RT. Staining with
DAPI was performed for 30 min at þ 37 1C. Then cells were washed with PBS and
fluorescence was evaluated with the DMRI Leica inverted microscope. The
percentage of pyknotic nuclei in the total number of nuclei was counted. For each
treatment 10 independent evaluations were taken.
The cell count was performed in the burker chamber. We measured the number
of cells in 1 ml of DMEM.
Flow cytometric analysis. To observe Met expression on cellular surface,
B2 105 cells, resuspended in 100ml of PBS added with 1% FBS, were stained
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20 min at RT, in the dark, with DN30 and DO24 mAbs previously conjugated with
PE-Cy7 fluorochrome (using Lightning-Link PE-Cy7 Tandem Conjugation Kit,
Innova Biosciences, Cambridge, UK). After wash, samples were analysed on a
CyAn ADP LX nine-color analyser (Beckman Coulter, Brea, CA, USA). Dead cells
were eliminated by excluding DAPI-positive population.
Wound-healing assay. Cells were plated in 24-well plates and maintained
in DMEM 10% FBS until confluence, and then were incubated in DMEM 0.5% FBS
for 18 h. The monolayers were wounded with a plastic pipette and a cross
between two lines was created. Then cells were washed with PBS and incubated
for 24, 48 and 72 h in medium with or without HGF, Met agonist mAbs or anti-VSV-
G mAb. Images of wound at the start moment and after the treatment were taken
with DMRI Leica inverted microscope. Migration was quantified by evaluating the
area of wound at time zero (A0) and at time after the treatment (Ay, y¼ 24 h, 48
or 72 h). Normalization and quantification on the basis of three independent
experiments were obtained by the formula (A0 Ay)/A0.
mRNA analysis: semi-quantitative reverse-transcription PCR
and real-time PCR. Total RNA was extracted with Trizol reagent, following the
manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA). Then RNA was quantified
with the NanoDrop ND-1000 and the reverse transcription was performed using High
Capacity cDNA Reverse Transcription Kit according to the manufacturer’s
recommendation (Applied Biosystem, Foster City, CA, USA). The cDNA was used
for real-time PCR analysis using the SsoFast EvaGreen supermix and the
MiniOpticon Thermal Cycler (Bio-Rad Laboratories) and for semi-quantitative RT-PCR
using various primers (see Supplementary Table S2). Control samples were prepared
without adding the RT enzyme to the reaction, and b-actin was used as control.
IF analysis. Cells plated in 24-well plates were fixed with ice-cold 4%
paraformaldehyde (PAF, Sigma) dissolved in PBS for 10 min and then washed
with PBS. In all the experiments, except for the membrane fluorescence of
Supplementary Figure S1b, left panel, the fixed cells were permeabilized with
0.1% Triton X-100 (Sigma). Then the cells were saturated with BSA (1%, Sigma)
and incubated with the primary antibody (See Supplementary Table S1) for 1 h at
RT. Secondary antibody incubation was performed with the Alexa Fluor 488-
conjugated goat anti-mouse or anti-rabbit antibody or with the Alexa Fluor
546-conjugated goat anti-mouse antibody (Molecular Probes/Invitrogen) for 1 h at
RT. DAPI was added at the end of secondary antibody incubation for 5 min at RT.
Images were taken through the DMRE Leica fluorescence microscope and
processed with LAS AF software (Leica Microsystems, Wetzlar, Germany).
Statistical analysis. All data are expressed as the mean±S.D. The
significant difference between the means taken from different samples was
analysed through independent two-tailed t-tests. P-value o0.05 was considered
statistically significant. For experimental details see each figure legend.
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